Plus   Neg

Agilent Gets FDA Approval For PD-L1 Companion Diagnostic On Dako Omnis

Agilent Technologies Inc. (A) said that the U.S. Food and Drug Administration has
approved the company's PD-L1 IHC 22C3 pharmDx as a companion diagnostic or CDx
to identify patients with non-small cell lung cancer who are appropriate for
first-line monotherapy with KEYTRUDA or pembrolizumab on the Dako Omnis platform.

Dako Omnis is Agilent's fully automated, walk-away solution for staining
tumor samples that provides a flexible, high-throughput diagnostic service
integrated into the core of the laboratory workflow.

Lung cancer is the leading cause of cancer-related mortality in the United
States, with an estimated incidence of 142,000 deaths in 2019 alone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT